摘要
目的：评价以紫杉醇为主的联合化疗对晚期乳腺癌患者的疗效和不良反应。方法：对２５ 例晚期或复发的乳腺癌患者行以紫杉醇为主的联合化疗，随机分成两组，Ａ 组：行以紫杉醇与顺铂、鬼臼乙叉甙的联合化疗；Ｂ组：行以紫杉醇与吡喃阿霉素的联合化疗。结果：初治组１０ 例，ＣＲ３ 例，ＰＲ４ 例，总有效率７００ ％ ；复治组１５ 例，ＰＲ６ 例，总有效率４００ ％ 。紫杉醇与顺铂、鬼臼乙叉甙联合化疗及紫杉醇与吡喃阿霉素联合化疗，两组疗效相近，但紫杉醇与吡喃阿霉素联合化疗骨髓抑制及消化道的不良反应相对较轻。
Purpose: To evaluate the treatment result and adverse effect of combination chemotherapy containing paclitaxel on patients with advanced breast cancer Methods: Combination chemotherapy containing paclitaxel was used on 25 patients with advanced breast cancer Two combination chemotherapy groups were divided randomly, they are group A: Taxol, DDP and VP-16 and group B: Taxol and THP Results: The total response rate (RR) in 10 primary patients was 70 0%, with 3 complete remission (CR), 4 partial remission (PR); in 15 retreated patients, the RR was 40 0%, with 6 PR, but no CR For comparison, no significant difference was observed in efficacy between combination chemotherapy of Taxol, DDP, VP-16 and Taxol and THP; but the bone marrow suppression and GI tract adverse effects for combination with Taxol plus THP were relatively weak Conclusion: Combination chemotherapy containing paclitaxel for patients with advanced breast cancer should be one of the first-rank treatment choices
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1999年第9期670-672,共3页
Chinese Journal of Clinical Oncology
关键词
柴杉醇
联合化疗
晚期
乳腺癌
治疗
Paclitaxel Combination chemotherapy Advanced breast cancer
